Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 21;22(15):7780.
doi: 10.3390/ijms22157780.

The Biology of Classic Hairy Cell Leukemia

Affiliations
Review

The Biology of Classic Hairy Cell Leukemia

Jan-Paul Bohn et al. Int J Mol Sci. .

Abstract

Classic hairy cell leukemia (HCL) is a rare mature B-cell malignancy associated with pancytopenia and infectious complications due to progressive infiltration of the bone marrow and spleen. Despite tremendous therapeutic advances achieved with the implementation of purine analogues such as cladribine into clinical practice, the culprit biologic alterations driving this fascinating hematologic disease have long stayed concealed. Nearly 10 years ago, BRAF V600E was finally identified as a key activating mutation detectable in almost all HCL patients and throughout the entire course of the disease. However, additional oncogenic biologic features seem mandatory to enable HCL transformation, an open issue still under active investigation. This review summarizes the current understanding of key pathogenic mechanisms implicated in HCL and discusses major hurdles to overcome in the context of other BRAF-mutated malignancies.

Keywords: B-cell receptor; BRAF V600E; DUSP; HCL; JNK; biology; epigenetic; fibronectin; hairy cell leukemia; methylome; microRNA; microenvironment; p38; single-cell sequencing; vitronectin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Current understanding of classic hairy cell leukemia biology. Line arrows with thunder illustrate evasion from pro-apoptotic signaling pathways; Dash arrows show proposed signaling outputs of constitutive ERK-signaling derived from preclinical data in BRAF-mutant melanoma cell lines; BRAF V600E, driver mutation in HCL; BCR, B-cell receptor; bFGF, basic fibroblast growth factor; BMSC, mesenchymal bone marrow stromal cells; BTK, Bruton’s tyrosine kinase; CXCL12, C-X-C motif chemokine 12; CXCR4, C-X-C chemokine receptor 4; DUSP, dual specificity phosphatase; ERK, extracellular-signal regulated kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; PKC, protein kinase C; PLCy, phospholipase C gamma; TGF, tumor growth factor; VCAM, vascular cell adhesion molecule; VLA, very late antigen, adhesion molecules.

References

    1. Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood. 2011;117:5019–5032. doi: 10.1182/blood-2011-01-293050. - DOI - PMC - PubMed
    1. Bouroncle B.A., Wiseman B.K., Doan C.A. Leukemic reticuloendotheliosis. Blood. 1958;13:609–630. doi: 10.1182/blood.V13.7.609.609. - DOI - PubMed
    1. Else M., Dearden C.E., Catovsky D. Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract. Res. Clin. Haematol. 2015;28:217–229. doi: 10.1016/j.beha.2015.09.004. - DOI - PMC - PubMed
    1. Dinmohamed A.G., Posthuma E.F.M., Visser O., Kater A.P., Raymakers R.A.P., Doorduijn J.K. Relative survival reaches a plateau in hairy cell leukemia: A population-based analysis in The Netherlands. Blood. 2018;131:1380–1383. doi: 10.1182/blood-2017-12-820381. - DOI - PubMed
    1. Schrek R., Donnelly W.J. “Hairy” cells in blood in lymphoreticular neoplastic disease and “flagellated” cells of normal lymph nodes. Blood. 1966;27:199–211. doi: 10.1182/blood.V27.2.199.199. - DOI - PubMed

Substances